HADIDA RUAH, SARA,MILLER, MARK,ZHOU, JINGLAN,BEAR, BRIAN,GROOTENHUIS, PETER, D
申请号：
NZ58598008
公开号：
NZ585980A
申请日:
2008.11.14
申请国别(地区):
NZ
年份:
2012
代理人:
摘要：
The disclosure relates to a substituted isoquinoline derivative of the structural formula shown herein and pharmaceutically acceptable salt thereof, which is useful as a modulator of ATP-Binding Cassette ("ABC") transporter activity, including Cystic Fibrosis Transmembrane Conductance Regulator ("CFTR"). Said substituted isoquinoline compound may be suitable for treating ABC transporter mediated diseases selected from cystic fibrosis, asthma, smoke induced COPD, chronic bronchitis, rhinosinusitis, constipation, pancreatitis, pancreatic insufficiency, male infertility caused by congenital bilateral absence of the vas deferens, mild pulmonary disease, idiopathic pancreatitis, allergic bronchopulmonary aspergillosis, liver disease, hereditary emphysema, hereditary hemochromatosis, coagulation-fibrinolysis deficiencies, lipid processing deficiencies, lysosomal storage diseases, Crigler-Najjar type II, polyendocrinopathy/hyperinsulemia, Diabetes mellitus, Laron dwarfism, myleoperoxidase deficiency, primary hypoparathyroidism, melanoma, glycanosis CDG type 1, congenital hyperthyroidism, osteogenesis imperfecta, hereditary hypofibrinogenemia, ACT deficiency, Diabetes insipidus, neurophyseal DI, neprogenic DI, Charcot-Marie Tooth syndrome, Perlizaeus-Merzbacher disease, neurodegenerative diseases several polyglutamine neurological disorders as well as spongiform encephalopathies, COPD, dry-eye disease and Sjogrens disease.
